RAS c.59/117 Mutation Detection Kit

Cat Number: RASX-RT50

The RAS c.59/117 Mutation Detection Kit is a rapid, real-time PCR assay for detection of KRAS c.59, NRAS c.59/117 somatic mutations used to help identify mCRC patients unlikely to benefit from EGFR-targeted therapy, enabling more informed and personalized treatment decisions

 

  • Below 1% Limit of Detection
  • 50 tests per kit
  • 2-hour turnaround time
  • Works with FFPE, fresh frozen and FNA samples
  • 3 Reactions per sample
  • For research use (RUO) in the U.S
  • For in vitro diagnostic use (IVD) in the European Union

The RAS c.59/117 Mutation Detection Kit is an add-on real-time PCR assay that detects rare somatic mutations in KRAS codon 59 and NRAS codon 59/117, complementing the commonly targeted mutations identified by the KRAS-RT50, NRAS-RT50, or KRBR-RT50 kits.

Designed exclusively for DNA isolated from formalin-fixed paraffin-embedded (FFPE) tissue, this kit enables comprehensive RAS mutation profiling in metastatic colorectal cancer samples that test negative for the more common mutations, ensuring more informed treatment decision-making.

Below is a list of mutations detected by this kit:

Gene Exon aa change nt change Cosmic ID
KRAS 3 A59T c.175G>A 546
A59E c.176C>A 547
A59G c.176c>G 28518
NRAS 3 A59T c.175G>A 578
A59D c.176C>A 253327
4 K117R c.350A>G 4696722

 

 

The RAS c.59/117 Mutation Detection Kit follows a simple and easy to use process. It can be completed in 2 hours and follows a far less complicated process.

EntroGenʼs RAS c.59/117 Mutation Detection Kit requires a real-time PCR instrument capable of detecting VIC and FAM fluorescent probes.

This test includes reagents required for PCR amplification/detection, as well as validated reaction controls.

Columns and reagents for DNA isolation are not included.

   

 

Comparison of KRAS Mutation Tests in Colorectal Cancer Patients. Poster presented at the 20th National Pathology Congress, Turkey, September 2010. Veysel Sabri Hançer, Gökhan Demir, İlknur Türkmen, Murat Büyükdoğan, Nuray Başsüllü, Tuncay Altuğ, Reyhan Diz-Küçükkaya, Gülen Bülbül-Doğusoy. Hancer VS, Buyukdogan M, Türkmen I, Bassullu N, Altug T, Diz-Kucukkaya R, Bulbul-Dogusoy G, Demir G. Genetic Test Mol Biomarkers. 2011 Jun 23. Pubmed ID 21699410
KRAS and BRAF Mutation Analysis in Colorectal Adenocarcinoma Specimens with a Low Percentage of Tumor Cells. Lewandowska MA, Jóźwicki W, Zurawski B. Mol Diagn Ther. 2013 Apr 20. Pubmed ID 23606169
Analysis of KRAS and BRAF Genes Mutation in the Central Nervous System Metastases of Non-Small Cell Lung Cancer. Nicoś M1, Krawczyk P, Jarosz B, Sawicki M, Szumiłło J, Trojanowski T, Milanowski J. Clin Exp Med. 2015 Apr 23. Pubmed ID 25902737
Cetuximab in Treatment of Metastatic Colorectal Cancer: Final Survival Analyses and Extended RAS Data from the NORDIC-VII Study. Guren, Thomsen, Kure, Sorbye, Glimelius, Pfeiffer, Österlund, Sigurdsson, Lothe, Dalsgaard, Skovlund, Christoffersen, Tveit. Comparison of KRAS Mutation Tests in Colorectal Cancer Patients. Br J Cancer. 2017 May 9;116(10):1271-1278. Pubmed ID 28399112
Analysis of KRAS, NRAS, BRAF, and PIK3CA Mutations Could Predict Metastases in Colorectal Cancer: A Preliminary Study. Wojas-Krawczyk K, Kalinka-Warzocha E, Reszka K, Nicoś M, Szumiło J, Mańdziuk S, Szczepaniak K, Kupnicka D, Lewandowski R, Milanowski J, Krawczyk P. Adv Clin Exp Med. 2018 Aug 7. Pubmed ID 30085422

Click to download lot-specific quality control data for your product:

Download